MCID: PRS047
MIFTS: 54

Prostatitis

Categories: Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Prostatitis

MalaCards integrated aliases for Prostatitis:

Name: Prostatitis 11 75 53 43 14 16 71

Classifications:



External Ids:

Disease Ontology 11 DOID:14654
ICD9CM 34 601.9
MeSH 43 D011472
NCIt 49 C26866
SNOMED-CT 68 155907007
ICD10 31 N41.9
UMLS 71 C0033581

Summaries for Prostatitis

MalaCards based summary: Prostatitis is related to prostate disease and paine syndrome, and has symptoms including prostatism An important gene associated with Prostatitis is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Saw palmetto and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include prostate, spinal cord and brain, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and homeostasis/metabolism

Wikipedia: 75 Prostatitis is inflammation of the prostate gland. Prostatitis is classified into acute, chronic,... more...

Related Diseases for Prostatitis

Diseases related to Prostatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 908)
# Related Disease Score Top Affiliating Genes
1 prostate disease 32.6 PCA3 KLK3 AR ACP3
2 paine syndrome 32.1 TNF IL6 IL1B IL10 CXCL8
3 prostatic hyperplasia, benign 31.4 PDE5A PCA3 KLK3 AR ACP3
4 urinary tract infection 31.4 TNF KLK3 IL6 IL1B IL10 CXCL8
5 interstitial cystitis 31.3 TNF IL6 IL1B
6 urethritis 31.1 TNF KLK3 IL6 IL1B IL17A IL10
7 chlamydia 31.1 TNF IL6 IL4 IL1B IL17A IL10
8 prostatic adenoma 31.1 KLK3 AR ACP3
9 pyelonephritis 31.0 TNF IL6 IL1B IL10 CXCL8
10 prostatic hypertrophy 30.9 PDE5A PCA3 KLK3 AR
11 cystitis 30.9 TNF PTGS2 IL6 IL4 IL2 IL17A
12 bladder neck obstruction 30.9 PDE5A KLK3
13 urinary tract obstruction 30.7 TNF KLK3 IL6 IL1B
14 acute pyelonephritis 30.7 TNF IL6 IL1B CXCL8
15 diphtheria 30.6 TNF IL4 IL2 IL1B
16 hemorrhoid 30.6 TNF KLK3 IL6 IL1B
17 orchitis 30.6 TNF IL6 IL2 IL1B IL17A IL10
18 cryptococcosis 30.6 TNF IL4 IL17A IL10
19 tetanus 30.5 TNF IL6 IL4 IL2 IL1B IL10
20 trichomoniasis 30.5 TNF IL6 IL1B IL10 CXCL8
21 melioidosis 30.5 TNF IL6 IL10
22 urolithiasis 30.5 VDR IL6 IL1B
23 endophthalmitis 30.5 TNF IL6 IL1B CXCL8
24 neurotic disorder 30.5 TNF IL6 IL1B
25 spondyloarthropathy 1 30.5 TNF IL6 IL1B IL17A IL10
26 diarrhea 30.4 TNF IL6 IL2 IL1B IL10 CXCL8
27 hypereosinophilic syndrome 30.4 IL4 IL2 IL10 CXCL8
28 anus disease 30.4 TNF KLK3 IL6 IL2
29 spondylitis 30.4 TNF IL6 IL1B IL17A IL10
30 urethral syndrome 30.4 TNF PDE5A KLK3 IL6 CXCL8
31 bladder cancer 30.4 TNF PTGS2 KLK3 IL6 IL2 IL10
32 varicocele 30.4 TNF IL6 BCL2 AR
33 irritable bowel syndrome 30.4 TNF IL6 IL4 IL1B IL17A IL10
34 haemophilus influenzae 30.3 TNF IL1B CXCL8
35 suppression of tumorigenicity 12 30.3 NKX3-1 KLK3 AR
36 fibromyalgia 30.3 TNF IL6 IL4 IL1B IL10 CXCL8
37 syphilis 30.3 TNF IL17A BCL2
38 anxiety 30.3 TNF IL6 IL1B IL10 CXCL8
39 pancreatitis 30.3 TNF IL6 IL1B IL10 CXCL8
40 meningoencephalitis 30.2 TNF IL6 IL1B IL10
41 pyelitis 30.2 TNF IL6 IL1B CXCL8
42 back pain 30.2 PTGS2 IL6 IL1B IL10 CXCL8
43 toxic shock syndrome 30.2 TNF IL6 IL4 IL2 IL1B IL10
44 osteomyelitis 30.2 TNF IL6 IL4 IL1B IL10 CXCL8
45 vasculitis 30.2 TNF IL6 IL1B IL17A IL10 CXCL8
46 alcoholic liver cirrhosis 30.2 TNF IL6 IL1B CXCL8
47 sclerosing cholangitis 30.2 TNF IL6 IL17A IL10
48 autoimmune disease 30.2 VDR TNF IL6 IL4 IL2 IL1B
49 cholangitis 30.2 TNF IL6 IL2 IL17A IL10 CXCL8
50 anterior uveitis 30.1 TNF IL6 IL2 IL1B IL17A IL10

Comorbidity relations with Prostatitis via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Epididymo-Orchitis Prostate Calculus
Prostate Cancer Prostatic Hypertrophy
Urethral Stricture Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostatitis:



Diseases related to Prostatitis

Symptoms & Phenotypes for Prostatitis

UMLS symptoms related to Prostatitis:


prostatism

GenomeRNAi Phenotypes related to Prostatitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 CXCL8 IL10 IL17A IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 CXCL8 IL10 IL17A IL1B IL2 TNF

MGI Mouse Phenotypes related to Prostatitis:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 AR BCL2 CCL3 IL10 IL17A IL1B
2 neoplasm MP:0002006 10.29 ACP3 AR BCL2 IL10 IL1B IL2
3 endocrine/exocrine gland MP:0005379 10.29 ACP3 AR BCL2 IL10 IL17A IL2
4 digestive/alimentary MP:0005381 10.23 AR BCL2 CCL3 IL10 IL17A IL2
5 liver/biliary system MP:0005370 10.21 AR IL10 IL17A IL2 IL4 IL6
6 immune system MP:0005387 10.21 AR BCL2 CCL3 IL10 IL17A IL1B
7 muscle MP:0005369 10.18 AR BCL2 IL10 IL6 KLK3 PROS1
8 no phenotypic analysis MP:0003012 10.14 IL10 IL17A IL2 IL4 NKX3-1 PROS1
9 cardiovascular system MP:0005385 10.14 AR BCL2 IL10 IL1B IL2 IL6
10 reproductive system MP:0005389 10.1 ACP3 AR BCL2 IL10 IL2 IL4
11 craniofacial MP:0005382 10.03 AR BCL2 IL10 IL17A IL1B IL4
12 skeleton MP:0005390 10 AR IL10 IL17A IL1B IL4 IL6
13 hematopoietic system MP:0005397 10 AR BCL2 CCL3 IL10 IL17A IL1B
14 mortality/aging MP:0010768 9.8 AR BCL2 CCL3 IL10 IL17A IL1B
15 integument MP:0010771 9.4 AR BCL2 IL10 IL17A IL1B IL4

Drugs & Therapeutics for Prostatitis

Drugs for Prostatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Saw palmetto Approved, Experimental, Investigational Phase 4
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Cycloserine Approved Phase 4 68-41-7 6234
4
Ibuprofen Approved Phase 4 15687-27-1 3672
5
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
6
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
7
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
8
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
9
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
10
Prulifloxacin Investigational Phase 4 123447-62-1 65947
11 Antibiotics, Antitubercular Phase 4
12 Anti-Bacterial Agents Phase 4
13 Acidophilus Phase 4
14 Anti-Infective Agents Phase 4
15 Saw palmetto extract Phase 4
16 Antimetabolites Phase 4
17 Antitubercular Agents Phase 4
18 Antirheumatic Agents Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Anti-Inflammatory Agents Phase 4
21 Analgesics, Non-Narcotic Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Neurotransmitter Agents Phase 4
24 Phosphodiesterase Inhibitors Phase 4
25 Analgesics Phase 4
26 Phosphodiesterase 5 Inhibitors Phase 4
27 Vasodilator Agents Phase 4
28 Anti-Anxiety Agents Phase 4
29 Psychotropic Drugs Phase 4
30 Anticonvulsants Phase 4
31 Citrate Phase 4
32 Excitatory Amino Acid Antagonists Phase 4
33
Pregabalin Approved, Investigational Phase 3 148553-50-8 5486971
34
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
35
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
36
Ofloxacin Approved Phase 3 82419-36-1 4583
37
Alfuzosin Approved, Investigational Phase 3 81403-80-7 2092
38
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
39
Dutasteride Approved, Investigational Phase 3 164656-23-9 6918296
40
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
41
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
42 calcium channel blockers Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 3
44 Phytosterol Phase 3
45 Antiviral Agents Phase 3
46 interferons Phase 3
47 Interferon-gamma Phase 3
48
abobotulinumtoxinA Phase 3
49 Pharmaceutical Solutions Phase 3
50 Botulinum Toxins, Type A Phase 3

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 Chronic Bacterial Prostatitis: Efficacy of Short-lasting Antibiotic Therapy With Prulifloxacin (Unidrox®) in Association With Saw Palmetto Extract, Lactobacillus Sporogens and Arbutin (Lactorepens®) Completed NCT02130713 Phase 4 Third generation fluoroquinolone
2 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward Completed NCT02246361 Phase 4
3 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
4 Effect of Non-steroidal Anti-inflammatory Drugs on Serum Prostate Specific Antigen Level Recruiting NCT05629494 Phase 4 Ibuprofen or Naproxen
5 Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
6 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
7 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
8 Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study Unknown status NCT03629769 Phase 3 Proxelan
9 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
10 Role of Dutasteride in Treatment of Category IIIB Chronic Prostatitis (A Placebo-Controlled Study) Completed NCT04756206 Phase 2, Phase 3 Dutasteride 0.5 mg;Placebo
11 A Multicenter, Double-Blind, Phase 3B Study to Compare the Safety and Clinical Efficacy of Levofloxacin in 750mg for 2 Weeks and Levofloxacin 750mg for 3 Weeks to That of Levofloxacin 500mg for 4 Weeks in the Treatment of Chronic Prostatitis Completed NCT00402688 Phase 3 levofloxacin
12 A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients Completed NCT00103402 Phase 3 Alfuzosin;Placebo
13 A Double Blind, Sham Controlled Trial Evaluating the Efficacy of Acupuncture in Relieving Symptoms of Chronic Prostatitis/ Chronic Pelvic Pain Syndrome Completed NCT00260637 Phase 2, Phase 3
14 A Multicenter, Double-Blind Study to Compare the Safety and Efficacy of Levofloxacin to That of Ciprofloxacin in the Treatment of Chronic Prostatitis Completed NCT00236808 Phase 3 levofloxacin
15 Prospective, Multinational, Multicenter, Non-Comparative, Open Study With a 6 Months Follow-up Period to Demonstrate the Efficacy and Safety of Oral Levofloxacin 500 mg Once Daily in the Treatment of Chronic Bacterial Prostatitis (CBP) Completed NCT00277511 Phase 3 Levofloxacin
16 Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-chronic Pelvic Pain Syndrome Completed NCT00919893 Phase 3 Cernilton;Placebo
17 An Open Controlled Study of the Efficacy and Safety of Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis Completed NCT05378646 Phase 3 Interferon gamma human recombinant (IFN-G)
18 A National, Multicentric, Randomised, Controlled Trial. Applications of a Critical Pathway Using Levofloxacin for the Management of Patients With Abnormal PSA. Completed NCT00169585 Phase 3 Levofloxacin oral tablets
19 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
20 A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Terminated NCT01830829 Phase 3 Jalyn;Placebo
21 Laparoscopic Prostatectomy for Chronic Prostatitis Unknown status NCT00775515 Phase 2
22 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
23 A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL GROUP PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIATED WITH CHRONIC ABACTERIAL PROSTATITIS Completed NCT00826514 Phase 2 Tanezumab;Placebo
24 Ciprofloxacin or Tamsulosin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Randomized, Double-blind Trial Completed NCT04552431 Phase 2 Ciprofloxacin;Tamsulosin Hydrochloride;Tamsulosin Hydrochloride Placebo;Ciprofloxacin placebo
25 A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
26 A Double-Blind, Randomized, Placebo-Controlled Trial of ELMIRON (Pentosan Polysulfate Sodium) for the Treatment of Chronic Non-Bacterial Prostatitis Completed NCT00236990 Phase 2 pentosan polysulfate sodium
27 Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis. Completed NCT03201796 Phase 2 Prulifloxacin 600 mg;Levofloxacin 500mg
28 A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of CP/CPPS Completed NCT01391338 Phase 2 ASP3652;Placebo
29 A Phase II Randomized Controlled Trial of a Supplement Containing Quercetin, Bromelain, Rye Flower Pollen, and Papain on Reducing the Severity of Radiation-Induced Prostatitis Recruiting NCT04252625 Phase 2 Q-Urol;Placebo
30 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain Terminated NCT00301405 Phase 2 Thalidomide
31 A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Terminated NCT03500159 Phase 2 AQX-1125 200 mg;Placebo
32 Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy Withdrawn NCT02961114 Phase 1, Phase 2
33 Real World Study on the Application of Appropriate Electrophysiological Technology in the Diagnosis and Treatment of Andrology Diseases in Northwest China Recruiting NCT04976751 Phase 1 Percutaneous electrical nerve stimulation treatment
34 A Prospective Pilot Study to Evaluate the Safety and Efficacy of Botox™ for the Treatment of Men Diagnosed With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Terminated NCT00529386 Phase 1 Botox
35 for Patients With Chronic Pelvic Pain Due to Chronic Prostatitis, do Combined Ganglion Impar Denervation and Pulsed Radiofrequency on Sacral Root 3 Acheive Better Analgesia Than Ganglion Impar Alone Unknown status NCT03884764
36 Multi-center Clinical Observation of a New Treatment Method Based on the Pathogenesis of Obstructive Prostatitis Unknown status NCT04128280
37 Comparison Between Applying Pulsed Radiofrequency to the Pudendal Nerve Bilaterally Vs Its Application to Sacral Nerve Roots S2,3 and 4 Bilaterally in the Improvement of Pain and Symptoms in Chronic Prostatitis, A Prospective Randomized Study Unknown status NCT03720951
38 Managment of Refractory Cases of Chronic Non Bacterial Prostatitis by TRUS Guided Injection of Betamethason Unknown status NCT04210739 Early Phase 1 Betamethason Sodium Phosphate
39 Efficacy Study of Tamsulosin and Tolterodine Treatment of Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome and Lower Urinary Tract Symptoms Unknown status NCT00913315 tolterodine;tamsulosin;placebo
40 Treatment of Chronic Prostatitis/ Pelvic Pain Syndrome With Low-intensity Extracorporeal Shockwave Therapy: A Prospective, Randomized, Single-blind, Cross-over Study Unknown status NCT04014036
41 The Comparison of Three Different Modes of Assessment on Acupuncture Effect on Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: a Study Protocol for a Randomized Controlled Trial Unknown status NCT03641807
42 The Efficacy of Extracorporal Shock Wave Therapy on Symptoms Relief in Patients With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome Unknown status NCT01714830
43 Urinary Tract Infection: RapID Molecular Organism Identification and Mixed Flora Antibiotic Resistance Profiling (MixAR) Unknown status NCT03931538
44 Shocking Therapy for Pelvic Pain: Evaluation of Shock Wave Therapy to Treat Chronic Pelvic Pain in Men Unknown status NCT01828996
45 Diagnostic Challenges in IC (and Male CPPS) Completed NCT00672087
46 Chemokine Mechanisms in Chronic Pelvic Pain Completed NCT01676857
47 Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT01843946
48 Non-interventional (Observational) Study of the Administration of Levolet® R, Film-coated Tablets (Dr. Reddy's Laboratories Ltd., India) in Adults With Chronic Prostatitis in Routine Clinical Practice Completed NCT02711943 Levofloxacin 500
49 Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Study Protocol for a Randomized, Placebo-controlled Trial Completed NCT02588274
50 Role of Residual Urine and Asymptomatic Prostatitis in the Development of Lower Urinary Tract Infections in Spinal Cord Injury Patients - a Prospective Study Completed NCT01601041

Search NIH Clinical Center for Prostatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin

Cochrane evidence based reviews: prostatitis

Genetic Tests for Prostatitis

Anatomical Context for Prostatitis

Organs/tissues related to Prostatitis:

MalaCards : Prostate, Spinal Cord, Brain, Dorsal Root Ganglion, Bone Marrow, Smooth Muscle, T Cells

Publications for Prostatitis

Articles related to Prostatitis:

(show top 50) (show all 6269)
# Title Authors PMID Year
1
Association between periodontal disease and prostate-specific antigen levels in chronic prostatitis patients. 53 62
20450358 2010
2
Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. 53 62
20177031 2010
3
[Clinical analysis of benign prostate hyperplasia with prostatitis]. 53 62
20448364 2010
4
Crucial role of interferon-gamma in experimental autoimmune prostatitis. 53 62
20096883 2010
5
Antibacterial therapy improves the effectiveness of prostate cancer detection using prostate-specific antigen in patients with asymptomatic prostatitis. 53 62
19548108 2010
6
Is it possible to predict sepsis, the most serious complication in prostate biopsy? 53 62
20224265 2010
7
Aggressiveness of inflammation in histological prostatitis--correlation with total and free prostate specific antigen levels in men with biochemical criteria for prostate biopsy. 53 62
19725275 2009
8
Prostate specific antigen, pelvic pain and prostatitis--time for a new paradigm? 53 62
19524944 2009
9
Management of elevated prostate-specific antigen in men with nonbacterial chronic prostatitis. 53 62
19570492 2009
10
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. 53 62
19603556 2009
11
Impact of vitamin D receptor activity on experimental autoimmune prostatitis. 53 62
19269787 2009
12
Influence of inflammation and aging on macrophage inhibitory cytokine-1 gene expression in rat ventral prostate. 53 62
18929399 2009
13
Incidence of histological prostatitis and its correlation with PSA density. 53 62
19936177 2009
14
Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA). 53 62
19111800 2009
15
[Wardenafil in combined treatment of patients with chronic bacterial prostatitis]. 53 62
19256057 2008
16
Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases. 53 62
18668524 2008
17
Control of autoimmune diseases by the vitamin D endocrine system. 53 62
18594491 2008
18
The issue of prostate cancer evaluation in men with elevated prostate-specific antigen and chronic prostatitis. 53 62
18336465 2008
19
Prevalence of delayed clinician response to elevated prostate-specific antigen values. 53 62
18380989 2008
20
PSA reduction (after antibiotics) permits to avoid or postpone prostate biopsy in selected patients. 53 62
17637759 2008
21
Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. 53 62
18836536 2008
22
Serum PSA and percent free PSA value changes after antibiotic treatment. A diagnostic method in prostate cancer suspects with asymptomatic prostatitis. 53 62
18362491 2008
23
Reduction of PSA values by combination pharmacological therapy in patients with chronic prostatitis: implications for prostate cancer detection. 53 62
17695414 2007
24
Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). 53 62
17241782 2007
25
The correlation between serum prostate specific antigen levels and asymptomatic inflammatory prostatitis. 53 62
17111077 2007
26
Serum prostate-specific antigen levels in Middle Eastern men with subclinical prostatitis. 53 62
17159365 2007
27
Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. 53 62
17300876 2007
28
Stage T2 prostate cancer presented with high serum prostate specific antigen and nonspecific bone lesions. 53 62
18595241 2007
29
Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin D receptor agonist elocalcitol. 53 62
17142748 2006
30
Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. 53 62
16890703 2006
31
Clinical significance of urinary white blood cell count and serum C-reactive protein level for detection of non-palpable prostate cancer. 53 62
16882055 2006
32
A sensitive proximity ligation assay for active PSA. 53 62
16800738 2006
33
Dealing with non-cancerous findings on prostate biopsy. 53 62
16630522 2006
34
The overlapping lower urinary tract symptoms of benign prostatic hyperplasia and prostatitis. 53 62
16385194 2006
35
Effects of chronic bacterial prostatitis on prostate specific antigen levels total and free in patients with benign prostatic hyperplasia and prostate cancer. 53 62
16502048 2006
36
Age-specific reference ranges for prostate specific antigen-total and free in patients with prostatitis symptoms and patients at risk. 53 62
17318358 2006
37
Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies? 53 62
16401916 2006
38
Pharmacological treatment for premature ejaculation. 53 62
16212722 2005
39
Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. 53 62
15993362 2005
40
[Asymptomatic prostatitis: a frequent cause of raising PSA]. 53 62
16209120 2005
41
Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen. 53 62
15947609 2005
42
The vicious cycling: bicycling related urogenital disorders. 53 62
15716187 2005
43
Pure prostatic papillary adenocarcinoma with ductal features. 53 62
15852679 2005
44
Ability of PSA-positive circulating macrophages to detect prostate cancer. 53 62
15389786 2005
45
PSA decrease after levofloxacin therapy in patients with histological prostatitis. 53 62
15693428 2004
46
Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer. 53 62
15636686 2004
47
[Effect of inflammatory chronic pelvic pain syndrome on the levels of prostatic specific antigen]. 53 62
15638019 2004
48
Effect of NIH-IV prostatitis on free and free-to-total PSA. 53 62
15548444 2004
49
Application of serum PSA to identify acute bacterial prostatitis in patients with fever of unknown origin or symptoms of acute pyelonephritis. 53 62
15264238 2004
50
Prostate carcinoma among men with human immunodeficiency virus infection. 53 62
15241826 2004

Variations for Prostatitis

Expression for Prostatitis

Search GEO for disease gene expression data for Prostatitis.

Pathways for Prostatitis

Pathways related to Prostatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 TNF PTGS2 PROS1 IL6 IL4 IL2
2
Show member pathways
13.92 BCL2 CCL3 CXCL8 IL10 IL17A IL1B
3 13.81 TNF PDE5A KLK3 IL6 IL2 CXCL8
4
Show member pathways
13.73 TNF PTGS2 IL6 IL4 IL2 IL1B
5
Show member pathways
13.63 TNF IL6 IL4 IL2 IL1B IL17A
6
Show member pathways
13.48 AR BCL2 CCL3 CXCL8 IL10 IL17A
7
Show member pathways
13.4 BCL2 CCL3 CXCL8 IL10 IL17A IL1B
8
Show member pathways
13.4 TNF PTGS2 IL6 IL4 IL2 IL1B
9
Show member pathways
12.96 BCL2 CCL3 CXCL8 IL1B IL2 IL6
10
Show member pathways
12.88 TNF IL6 IL4 IL2 BCL2
11
Show member pathways
12.8 IL1B IL2 PTGS2 TNF VDR
12
Show member pathways
12.77 TNF IL6 IL4 IL2 IL1B IL17A
13
Show member pathways
12.73 BCL2 IL10 IL17A IL1B IL2 IL6
14 12.7 TNF PTGS2 IL4 IL2 IL1B IL17A
15
Show member pathways
12.69 TNF PTGS2 IL6 IL1B CXCL8
16
Show member pathways
12.54 TNF IL6 IL1B CXCL8
17
Show member pathways
12.52 TNF IL6 IL4 IL1B CXCL8
18
Show member pathways
12.42 TNF PTGS2 IL6 IL1B CXCL8
19
Show member pathways
12.4 TNF PTGS2 IL6 IL17A CXCL8
20
Show member pathways
12.28 IL10 IL17A IL2 IL4 TNF
21 12.27 TNF NKX3-1 IL6 IL1B IL10 CXCL8
22 12.22 TNF IL6 IL4 IL1B IL10 BCL2
23 12.14 TNF IL6 IL4 IL2 IL10
24 12.09 BCL2 CCL3 CXCL8 IL1B IL6
25
Show member pathways
12.07 IL4 IL2 IL1B CCL3
26 12.06 TNF PTGS2 IL6 IL4 IL2 IL1B
27
Show member pathways
12.03 IL10 IL17A IL1B IL2 IL6 TNF
28 12 IL6 IL10 CXCL8 CCL3
29
Show member pathways
11.98 IL6 IL4 IL1B IL17A
30 11.92 TNF IL6 IL1B CXCL8 BCL2
31 11.92 TNF IL4 IL2 IL1B IL17A IL10
32 11.91 TNF IL6 IL2 IL1B IL10
33 11.9 IL6 IL4 IL2 CXCL8
34 11.89 IL6 IL2 IL10 BCL2
35 11.88 IL2 CXCL8 BCL2
36 11.88 TNF IL6 IL4 IL2 IL10
37 11.86 IL6 IL4 IL2 IL1B IL17A
38 11.86 IL6 IL4 IL2 IL10 CXCL8
39
Show member pathways
11.84 CXCL8 IL2 IL4 PTGS2 TNF
40 11.82 TNF IL4 IL2 IL1B IL17A IL10
41 11.8 TNF IL6 IL1B IL10
42 11.8 TNF IL6 IL10 CXCL8 CCL3
43 11.79 VDR IL10 AR
44 11.79 CCL3 CXCL8 IL1B IL4 IL6 TNF
45
Show member pathways
11.77 TNF IL6 IL4 IL2 IL10
46
Show member pathways
11.77 CXCL8 IL1B IL2 IL6 PTGS2 TNF
47 11.7 NKX3-1 KLK3 AR
48 11.7 TNF IL10 CXCL8 CCL3
49 11.7 VDR TNF IL6 CXCL8
50 11.67 IL6 CXCL8 BCL2

GO Terms for Prostatitis

Cellular components related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.03 TNF PROS1 MSMB KLK3 IL6 IL4
2 extracellular space GO:0005615 9.74 ACP3 CCL3 CXCL8 IL10 IL17A IL1B

Biological processes related to Prostatitis according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.52 AR IL10 IL17A IL1B IL2 IL4
2 cell-cell signaling GO:0007267 10.37 IL2 IL1B IL17A CCL3 AR
3 negative regulation of apoptotic process GO:0043066 10.36 BCL2 IL10 IL2 IL4 IL6 PTGS2
4 inflammatory response GO:0006954 10.36 CCL3 CXCL8 IL17A IL1B IL6 PTGS2
5 MAPK cascade GO:0000165 10.31 TNF IL1B CCL3 AR
6 positive regulation of cell population proliferation GO:0008284 10.31 PTGS2 NKX3-1 IL6 IL4 IL2 IL1B
7 defense response to Gram-positive bacterium GO:0050830 10.29 IL17A IL1B IL6 TNF
8 positive regulation of inflammatory response GO:0050729 10.26 CCL3 IL1B IL2 TNF
9 positive regulation of interleukin-6 production GO:0032755 10.26 TNF IL6 IL1B IL17A
10 cellular response to lipopolysaccharide GO:0071222 10.24 TNF IL6 IL1B IL10 CXCL8
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.21 TNF PTGS2 IL6 BCL2
12 cellular response to interleukin-1 GO:0071347 10.21 CCL3 CXCL8 IL17A NKX3-1
13 positive regulation of B cell proliferation GO:0030890 10.18 IL4 IL2 BCL2
14 positive regulation of DNA-binding transcription factor activity GO:0051091 10.18 TNF NKX3-1 IL6 IL1B IL10
15 positive regulation of nitric oxide biosynthetic process GO:0045429 10.17 TNF PTGS2 IL1B
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.17 TNF IL6 IL4 IL2
17 lipopolysaccharide-mediated signaling pathway GO:0031663 10.16 TNF IL1B CCL3
18 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 10.16 TNF IL1B BCL2
19 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.16 TNF IL6 IL10
20 positive regulation of interleukin-1 beta production GO:0032731 10.16 CCL3 IL17A IL6 TNF
21 liver regeneration GO:0097421 10.13 IL10 IL6 TNF
22 positive regulation of vascular endothelial growth factor production GO:0010575 10.12 PTGS2 IL6 IL1B
23 positive regulation of immunoglobulin production GO:0002639 10.11 IL6 IL2 IL10
24 positive regulation of gene expression GO:0010628 10.11 AR CCL3 CXCL8 IL1B IL4 IL6
25 positive regulation of chemokine production GO:0032722 10.1 TNF IL6 IL1B
26 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.1 TNF IL6 IL17A
27 protein kinase B signaling GO:0043491 10.1 TNF NKX3-1 IL1B CCL3
28 negative regulation of neurogenesis GO:0050768 10.09 TNF IL6 IL1B
29 positive regulation of T cell proliferation GO:0042102 10.09 IL6 IL4 IL2 IL1B
30 response to radiation GO:0009314 10.06 TNF PTGS2 BCL2
31 regulation of sensory perception of pain GO:0051930 10.06 IL10 CCL3 ACP3
32 positive regulation of glial cell proliferation GO:0060252 10.05 TNF IL6 IL1B
33 negative regulation of mitotic cell cycle GO:0045930 10.03 BCL2 IL10 TNF
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.01 TNF IL1B IL10
35 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 10.01 IL4 IL2 IL1B BCL2
36 negative regulation of cytokine production involved in immune response GO:0002719 10 IL10 TNF
37 positive regulation of mononuclear cell migration GO:0071677 10 IL4 TNF
38 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.99 TNF NKX3-1
39 response to fructose GO:0009750 9.99 TNF PTGS2
40 sequestering of triglyceride GO:0030730 9.98 IL1B TNF
41 regulation of isotype switching GO:0045191 9.97 IL10 IL4
42 response to glucocorticoid GO:0051384 9.96 TNF PTGS2 IL6 IL10 BCL2
43 positive regulation of plasma cell differentiation GO:1900100 9.94 IL2 IL10
44 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.94 TNF IL1B
45 positive regulation of neuroinflammatory response GO:0150078 9.93 IL1B IL6 TNF
46 chronic inflammatory response to antigenic stimulus GO:0002439 9.9 TNF IL10
47 vascular endothelial growth factor production GO:0010573 9.85 IL1B IL6 TNF
48 positive regulation of fever generation GO:0031622 9.8 TNF PTGS2 IL1B
49 immune response GO:0006955 9.77 TNF IL6 IL4 IL2 IL1B IL17A
50 negative regulation of cell population proliferation GO:0008285 9.58 VDR TNF PTGS2 NKX3-1 IL6 IL1B

Molecular functions related to Prostatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.53 TNF IL6 IL4 IL2 IL1B IL17A

Sources for Prostatitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....